Pharvaris N.V. PHVS
35.17 USD +0.77 (+2.25%)
Nov 9, 2026, 10:06 AM EST
34.40 Day range 35.42
21.59 52-week range 38.86
- YTD
- +26.72%
- 1 year
- +62.88%
News
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
benzinga.com This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
benzinga.com This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday Analysts upgraded Pentair to Neutral with a $65 target and Sun Life Financial to Outperform, raising its target to C$122.
benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
benzinga.com Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.
benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44 B of A Securities analyst Tazeen Ahmad upgrades Pharvaris (NASDAQ:PHVS) from Neutral to Buy and maintains the price target from $44 to $44.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR…
benzinga.com Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44 Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $40 to $44.
benzinga.com Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62 Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.- benzinga.com Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65 Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $50 to $65.
benzinga.com Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65 Wells Fargo analyst Yanan Zhu maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $55 to $65.
benzinga.com RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62 RBC Capital analyst Nevin Varghese maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $52 to $62.- benzinga.com Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79 Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $75 to $79.
benzinga.com Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.- benzinga.com Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $50 Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $42 to $50.
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy and maintains $60 price target.
benzinga.com Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
benzinga.com Why Is Pharvaris Stock Soaring Tuesday? Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…- benzinga.com Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in…
- benzinga.com RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52 RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $51 to $52.
benzinga.com Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40 Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $39 to $40.- benzinga.com Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75 Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $74 to $75.
- benzinga.com Pharvaris Q2 EPS $(0.81) Misses $(0.74) Estimate Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 13.83 percent increase over losses of $(0.94)…
- benzinga.com Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for…
- benzinga.com Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55 Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rating and announces Price Target of $55.
benzinga.com Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027 If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical program demonstrating rapid relief and…- benzinga.com Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46 Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.
- benzinga.com Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema,…
- benzinga.com Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74 Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $75 to $74.
- benzinga.com Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.77) by 10.39 percent. This is a 22.47 percent increase over losses of $(0.89)…
- benzinga.com Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 581,199 ordinary shares at the public…
- benzinga.com Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In Combination With Deucrictibant XR Tablet At CIIC Spring 2026 Conference Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases…
- benzinga.com Wolfe Research Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $42 Wolfe Research analyst Andy Chen initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform rating and announces Price Target of $42.
- benzinga.com Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $42 Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $41 to $42.
benzinga.com Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to the stock, says Guggenheim analyst.- benzinga.com RBC Capital Maintains Outperform on Pharvaris, Lowers Price Target to $51 RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers the price target from $52 to $51.
benzinga.com Earnings Scheduled For April 2, 2026 - benzinga.com Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.69) by 21.74 percent. This is a 23.53 percent decrease over losses of $(0.68)…
- benzinga.com Pharvaris Announces Publication Of Data From Two Randomized Phase 2 Studies, CHAPTER-1 And RAPIDe-1, Evaluating Efficacy And Safety Of Deucrictibant For Prophylaxis And On-Demand Treatment Of HAE Attacks, In The Lancet Haematology Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAEZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE)…
- benzinga.com Pharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑Demand Treatment Endpoints Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of…
benzinga.com RBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52 RBC Capital analyst Brian Abrahams initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform rating and announces Price Target of $52.- benzinga.com HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy and maintains $60 price target.
- benzinga.com Pharvaris Summarized The Presentations For The American Academy Of Allergy, Asthma & Immunology Annual Meeting For Deucrictibant For On-Demand And Prophylactic Treatment Of Bradykinin-mediated Angioedema RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance with deucrictibant achieving onset of symptom relief in 1.28 hours and complete symptom resolution…
- benzinga.com Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $50 Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $44 to $50.
- benzinga.com Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $39 Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $32 to $39.
- benzinga.com Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41 Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $37 to $41.